359 related articles for article (PubMed ID: 31598114)
1. Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.
Fiordelisi MF; Auletta L; Meomartino L; Basso L; Fatone G; Salvatore M; Mancini M; Greco A
Contrast Media Mol Imaging; 2019; 2019():8946729. PubMed ID: 31598114
[TBL] [Abstract][Full Text] [Related]
2. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
Al-Saden N; Lam K; Chan C; Reilly RM
Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
[TBL] [Abstract][Full Text] [Related]
3. Monitoring Src status after dasatinib treatment in HER2+ breast cancer with
McKnight BN; Viola-Villegas NT
Breast Cancer Res; 2018 Oct; 20(1):130. PubMed ID: 30359299
[TBL] [Abstract][Full Text] [Related]
4. TNFα-Induced Mucin 4 Expression Elicits Trastuzumab Resistance in HER2-Positive Breast Cancer.
Mercogliano MF; De Martino M; Venturutti L; Rivas MA; Proietti CJ; Inurrigarro G; Frahm I; Allemand DH; Deza EG; Ares S; Gercovich FG; Guzmán P; Roa JC; Elizalde PV; Schillaci R
Clin Cancer Res; 2017 Feb; 23(3):636-648. PubMed ID: 27698002
[TBL] [Abstract][Full Text] [Related]
5. Monitoring Trastuzumab Resistance and Cardiotoxicity: A Tale of Personalized Medicine.
Dokmanovic M; Wu WJ
Adv Clin Chem; 2015; 70():95-130. PubMed ID: 26231486
[TBL] [Abstract][Full Text] [Related]
6. Multitargeted therapy in estrogen receptor-positive, human epidermal growth factor receptor-2-positive breast cancer.
Nahleh ZA; Jazieh AR
Am J Clin Oncol; 2005 Dec; 28(6):631-3. PubMed ID: 16317277
[No Abstract] [Full Text] [Related]
7. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
García Vicente AM; Soriano Castrejón A; Relea Calatayud F; Muñoz Madero V; Molina Garrido MJ; León Martín AA; Cordero García JM; Pilkington Woll JP; Chacón López-Muñiz I; Palomar Muñoz A
Rev Esp Med Nucl Imagen Mol; 2012; 31(6):308-14. PubMed ID: 23084013
[TBL] [Abstract][Full Text] [Related]
8. [Therapeutic targeting in breast cancer].
Penault-Llorca F
Ann Pathol; 2009 Nov; 29 Spec No 1():S71-3. PubMed ID: 19887259
[No Abstract] [Full Text] [Related]
9. Molecular Imaging and Precision Medicine in Breast Cancer.
Chudgar AV; Mankoff DA
PET Clin; 2017 Jan; 12(1):39-51. PubMed ID: 27863565
[TBL] [Abstract][Full Text] [Related]
10. Noninvasive Detection of HER2 Expression in Gastric Cancer by
Guo X; Zhu H; Zhou N; Chen Z; Liu T; Liu F; Xu X; Jin H; Shen L; Gao J; Yang Z
Mol Pharm; 2018 Nov; 15(11):5174-5182. PubMed ID: 30251865
[TBL] [Abstract][Full Text] [Related]
11. Insights into biology of luminal HER2 vs. enriched HER2 subtypes: Therapeutic implications.
Harbeck N
Breast; 2015 Nov; 24 Suppl 2():S44-8. PubMed ID: 26321480
[TBL] [Abstract][Full Text] [Related]
12. New advance in breast cancer pathology and imaging.
Urbano N; Scimeca M; Bonfiglio R; Bonanno E; Schillaci O
Future Oncol; 2019 Aug; 15(23):2707-2722. PubMed ID: 31339050
[TBL] [Abstract][Full Text] [Related]
13. Advancing novel molecular imaging agents from preclinical studies to first-in-humans phase I clinical trials in academia--a roadmap for overcoming perceived barriers.
Reilly RM; Lam K; Chan C; Levine M
Bioconjug Chem; 2015 Apr; 26(4):625-32. PubMed ID: 25781873
[TBL] [Abstract][Full Text] [Related]
14. Molecular Breast Cancer Imaging in the Era of Precision Medicine.
Muzahir S
AJR Am J Roentgenol; 2020 Dec; 215(6):1512-1519. PubMed ID: 33084364
[No Abstract] [Full Text] [Related]
15. Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Cristofanilli M; DeMichele A; Giorgetti C; Turner NC; Slamon DJ; Im SA; Masuda N; Verma S; Loi S; Colleoni M; Theall KP; Huang X; Liu Y; Bartlett CH
Eur J Cancer; 2018 Nov; 104():21-31. PubMed ID: 30308388
[TBL] [Abstract][Full Text] [Related]
16. Molecular Imaging and Precision Medicine in Uterine and Ovarian Cancers.
Zukotynski KA; Kim CK
PET Clin; 2017 Oct; 12(4):393-405. PubMed ID: 28867111
[TBL] [Abstract][Full Text] [Related]
17. An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression.
Schwarz LJ; Hutchinson KE; Rexer BN; Estrada MV; Gonzalez Ericsson PI; Sanders ME; Dugger TC; Formisano L; Guerrero-Zotano A; Red-Brewer M; Young CD; Lantto J; Pedersen MW; Kragh M; Horak ID; Arteaga CL
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059433
[TBL] [Abstract][Full Text] [Related]
18. A rapid and quantitative method to detect human circulating tumor cells in a preclinical animal model.
Tu SH; Hsieh YC; Huang LC; Lin CY; Hsu KW; Hsieh WS; Chi WM; Lee CH
BMC Cancer; 2017 Jun; 17(1):440. PubMed ID: 28645267
[TBL] [Abstract][Full Text] [Related]
19. Molecular imaging using PET for breast cancer.
Kurihara H; Shimizu C; Miyakita Y; Yoshida M; Hamada A; Kanayama Y; Yonemori K; Hashimoto J; Tani H; Kodaira M; Yunokawa M; Yamamoto H; Watanabe Y; Fujiwara Y; Tamura K
Breast Cancer; 2016 Jan; 23(1):24-32. PubMed ID: 25917108
[TBL] [Abstract][Full Text] [Related]
20. Molecular imaging of breast cancer.
Oude Munnink TH; Nagengast WB; Brouwers AH; Schröder CP; Hospers GA; Lub-de Hooge MN; van der Wall E; van Diest PJ; de Vries EG
Breast; 2009 Oct; 18 Suppl 3():S66-73. PubMed ID: 19914546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
